<?xml version='1.0' encoding='utf-8'?>
<document id="27895236"><sentence text="Single-Tablet Regimens for the Treatment of HIV-1 Infection." /><sentence text="To review the pharmacokinetics, safety, drug-drug interactions, and advantages and disadvantages of currently available single-tablet regimens (STRs) for HIV-1 infection" /><sentence text="" /><sentence text="A search using PubMed was conducted (up to September 2016) using the following keywords: single tablet regimen AND HIV" /><sentence text=" Additionally, a PubMed search was conducted for each individual STR using the generic names of the agents" /><sentence text=" Articles were evaluated for content, and additional references were identified from a review of literature citations" /><sentence text="" /><sentence text="Studies included were predominantly phase III clinical trials with the exception of tenofovir alafenamide because phase I and phase II trials were also relevant for this new antiretroviral agent"><entity charOffset="84-105" id="DDI-PubMed.27895236.s8.e0" text="tenofovir alafenamide" /></sentence><sentence text="" /><sentence text="Six STRs are currently available for the treatment of HIV-1" /><sentence text=" Each agent has unique pharmacokinetic, safety, and drug-drug interaction profiles that result in distinct advantages and disadvantages" /><sentence text=" Three of these agents are first-line recommended therapies per national guidelines because of high virological efficacy and tolerability" /><sentence text="" /><sentence text="STRs have significantly advanced HIV management by minimizing pill burden and improving patient compliance" /><sentence text=" It is important to consider the nuances of each STR in regard to renal and hepatic function, drug interactions, and tolerability, to ensure safe and effective use" /><sentence text="" /></document>